<DOC>
	<DOCNO>NCT02689921</DOCNO>
	<brief_summary>This prospective , single-arm , phase II study 32 evaluable patient treat NEOADjuvant Aromatase inhibitor Pertuzumab/Trastuzumab ( NEOADAPT ) without chemotherapy hormone receptor positive ( HR+ ) , [ i.e . Estrogen Receptor positive ( ER+ ) and/or Progesterone Receptor positive ( PR+ ) ] HER2+ localize , non-metastatic stage I - IIb breast cancer .</brief_summary>
	<brief_title>NEOADjuvant Aromatase Inhibitor Pertuzumab/Trastuzumab Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Ability provide sign , write informed consent Histologically cytologically confirm nonmetastatic adenocarcinoma breast ( stage III ) Candidate curativeintent treatment ER+ and/or PR+ HER2positive ( Fluorescence In Situ Hybridizationpositive 3+ Immunohistochemistry staining ) Life expectancy great 5 year Left Ventricular Ejection Fraction &gt; 50 % baseline ( within 30 day day 0 ) Eastern Cooperative Oncology Group performance status ≤2 Absolute Neutrophil Count &gt; 1000/µL Platelets ≥50,000/µL Hemoglobin &gt; 8.0 g/dL , Creatinine ≤3.0 x upper limit normal ( ULN ) Bilirubin ≤3.0 x ULN Aspartate aminotransferase Alanine aminotransferase &lt; 5.0 x ULN Negative serum pregnancy test woman &lt; 12 month onset menopause unless surgically sterilize Agreement woman childbearing potential male participant partner childbearing potential use `` highly effective '' , nonhormonal form contraception two `` effective '' form nonhormonal contraception patient and/or partner . Active infection Presence know metastasis ( stage IV disease ) Pregnant lactate woman Prior chemotherapy radiation therapy primary breast cancer Concomitant malignancies previous malignancy within last 5 year except adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . History significant cardiac disease , cardiac risk factor uncontrolled arrhythmias Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary metabolic disease include diabetes , wound heal disorder , ulcer bone fracture ) Major surgical procedure significant traumatic injury within 28 day prior study treatment start anticipate need major surgery course study treatment Current know infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B virus ( HBV ) Hepatitis C Virus ( HCV ) Receipt intravenous antibiotic infection within 14 day prior receive study treatment Current chronic daily treatment corticosteroid ( dose &gt; 10 mg/day methylprednisolone equivalent ) except inhaled steroid Known hypersensitivity study drug Assessment investigator unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>